Valley Wealth Managers Inc. Acquires 207,642 Shares of Pfizer Inc. $PFE

Valley Wealth Managers Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 28.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 948,832 shares of the biopharmaceutical company’s stock after purchasing an additional 207,642 shares during the period. Pfizer comprises 1.7% of Valley Wealth Managers Inc.’s holdings, making the stock its 18th biggest position. Valley Wealth Managers Inc.’s holdings in Pfizer were worth $26,643,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Penn Davis Mcfarland Inc. lifted its position in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after buying an additional 57,777 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. KBC Group NV grew its position in shares of Pfizer by 8.3% in the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock worth $228,924,000 after buying an additional 706,426 shares during the last quarter. Pensionfund Sabic bought a new position in shares of Pfizer during the 4th quarter worth approximately $1,863,000. Finally, North Dakota State Investment Board purchased a new stake in Pfizer during the fourth quarter valued at approximately $5,348,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.2%

PFE stock opened at $25.08 on Friday. The stock has a market capitalization of $142.94 billion, a PE ratio of 19.15 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average of $25.21 and a 200 day moving average of $26.17.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Finally, Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.